Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma

Aitua Salami, Thaer Obaid, Amit R T Joshi

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


BACKGROUND: We assessed trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma.

METHODS: A retrospective cohort study using data from the SEER program (2004-2014). All patients diagnosed with pancreatic adenocarcinoma over 2 eras were included (A: 2004-2009 vs. B: 2010-2014). Outcomes of interest were the likelihood of metastatic disease at diagnosis, utilization of resection, and overall survival.

RESULTS: A total of 62,201 patients were included in this study [Era B - 31,998 (51.4%)]. Patients diagnosed in Era B were significantly less likely to have metastatic pancreatic cancer at diagnosis, and demonstrated improved long-term survival after risk-adjustment. Similarly, patients with non-metastatic pancreatic cancer that were diagnosed in Era B were independently more likely to undergo resection. The observed association between era of diagnosis and survival was independent of resection status and the presence of metastatic disease.

CONCLUSIONS: There have been significant improvements in pancreatic cancer care over the last decade, as evidenced by earlier diagnosis, increased utilization of surgery, and improvement in overall survival for both resected and un-resected patients.

Original languageEnglish (US)
Pages (from-to)103-107
Number of pages5
JournalAmerican journal of surgery
Issue number1
StatePublished - Jan 2019
Externally publishedYes

Bibliographical note

Copyright © 2018 Elsevier Inc. All rights reserved.


  • Adenocarcinoma/diagnosis
  • Adult
  • Aged
  • Early Detection of Cancer
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatectomy
  • Pancreatic Neoplasms/diagnosis
  • Retrospective Studies
  • SEER Program
  • Survival Rate

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this